James Condulis
Stock Analyst at Stifel Nicolaus
(0.49)
# 4,452
Out of 5,189 analysts
75
Total ratings
30.6%
Success rate
-7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AARD Aardvark Therapeutics | Maintained: Hold | $6 → $2 | $0.9226 | +116.78% | 6 | Nov 19, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterated: Buy | $104 → $96 | $41.37 | +132.05% | 4 | Nov 13, 2026 | |
| BRVE Braveheart Bio | Reiterated: Buy | $45 | $20.39 | +120.70% | 5 | Nov 9, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Buy | $50 | $18.41 | +171.59% | 7 | Nov 9, 2026 | |
| TECX Tectonic Therapeutic | Reiterated: Buy | $75 | $20.73 | +261.79% | 5 | Nov 6, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $108 | $50.78 | +112.68% | 17 | Nov 5, 2026 | |
| EWTX Edgewise Therapeutics | Reiterated: Hold | $36 | $39.91 | -9.79% | 7 | Nov 5, 2026 | |
| XFOR X4 Pharmaceuticals | Reiterated: Buy | $10 | $3.00 | +233.33% | 4 | Nov 5, 2026 | |
| MIRM Mirum Pharmaceuticals | Reiterated: Buy | $156 | $96.13 | +62.28% | 10 | Nov 4, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $45 | $26.02 | +72.94% | 3 | Oct 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $5.56 | +223.74% | 1 | Sep 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.69 | - | 6 | Sep 21, 2026 |
Aardvark Therapeutics
Nov 19, 2026
Maintained: Hold
Price Target: $6 → $2
Current: $0.9226
Upside: +116.78%
Arrowhead Pharmaceuticals
Nov 13, 2026
Reiterated: Buy
Price Target: $104 → $96
Current: $41.37
Upside: +132.05%
Braveheart Bio
Nov 9, 2026
Reiterated: Buy
Price Target: $45
Current: $20.39
Upside: +120.70%
NewAmsterdam Pharma Company
Nov 9, 2026
Reiterated: Buy
Price Target: $50
Current: $18.41
Upside: +171.59%
Tectonic Therapeutic
Nov 6, 2026
Reiterated: Buy
Price Target: $75
Current: $20.73
Upside: +261.79%
Cytokinetics
Nov 5, 2026
Reiterated: Buy
Price Target: $108
Current: $50.78
Upside: +112.68%
Edgewise Therapeutics
Nov 5, 2026
Reiterated: Hold
Price Target: $36
Current: $39.91
Upside: -9.79%
X4 Pharmaceuticals
Nov 5, 2026
Reiterated: Buy
Price Target: $10
Current: $3.00
Upside: +233.33%
Mirum Pharmaceuticals
Nov 4, 2026
Reiterated: Buy
Price Target: $156
Current: $96.13
Upside: +62.28%
Amylyx Pharmaceuticals
Oct 1, 2026
Reiterated: Buy
Price Target: $45
Current: $26.02
Upside: +72.94%
Sep 30, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $5.56
Upside: +223.74%
Sep 21, 2026
Rated: Hold
Price Target: n/a
Current: $3.69
Upside: -